🇺🇸 FDA
Patent

US 9334246

Substituted triazines for malaria treatment and chemoprophylaxis

granted A61KA61K31/53A61K31/5377

Quick answer

US patent 9334246 (Substituted triazines for malaria treatment and chemoprophylaxis) held by The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research
Grant date
Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/53, A61K31/5377, A61K45/06, A61P